

EDITORIAL

SKELETAL MUSCLE DYSFUNCTION IN COPD: **NOVELTIES IN THE LAST DECADE**

Autor: Esther Barreiro

¹Pulmonology Department-Muscle Wasting and Cachexia in Chronic Respiratory Diseases and Lung Cancer, IMIM-*Hospital del Mar*, Health and Experimental Sciences Department (CEXS), *Universitat Pompeu Fabra* (UPF), Barcelona Biomedical Research Park (PRBB), C/ Dr. Aiguader, 88, Barcelona.

²*Centro de Investigación en Red de Enfermedades Respiratorias* (CIBERES), *Instituto de Salud Carlos III* (ISCIII), Barcelona, Spain.

e-mail: ebarreiro@imim.es

AGRADECIMIENTOS: CIBERES, FIS 14/00713, SEPAR 2013, SEPAR 2016, FUCAP 2011, FUCAP 2012, FUCAP 2014, FUCAP 2016.

CONFLICT OF INTEREST: The author declares that no conflict of interest exists in relation to this manuscript

Word count: 996

EDITORIAL

SKELETAL MUSCLE DYSFUNCTION IN COPD: NOVELTIES IN THE LAST DECADE

¹Pulmonology Department-Muscle Wasting and Cachexia in Chronic Respiratory Diseases and Lung Cancer, IMIM-*Hospital del Mar*, Health and Experimental Sciences Department (CEXS), *Universitat Pompeu Fabra* (UPF), Barcelona Biomedical Research Park (PRBB), C/ Dr. Aiguader, 88, Barcelona.

²*Centro de Investigación en Red de Enfermedades Respiratorias* (CIBERES), *Instituto de Salud Carlos III* (ISCIII), Barcelona, Spain.

e-mail: ebarreiro@imim.es

AGRADECIMIENTOS: CIBERES, FIS 14/00713, SEPAR 2013, SEPAR 2016, FUCAP 2011, FUCAP 2012, FUCAP 2014, FUCAP 2016.

CONFLICT OF INTEREST: The author declares that no conflict of interest exists in relation to this manuscript

Word count: 996

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

EDITORIAL

1
2 Skeletal muscle dysfunction, characterized by impaired strength and/or endurance
3
4 properties of muscles, is a relevant systemic manifestation in patients with chronic cardiac
5
6 and respiratory conditions such as chronic obstructive pulmonary disease (COPD). Muscle
7
8 dysfunction negatively affects exercise capacity in the patients, thus diminishing their
9
10 quality of life. Furthermore, muscle dysfunction and wasting of the lower limbs has been
11
12 shown to predict disease morbidity and mortality regardless of the airway obstruction¹⁻³.
13
14 Several factors and biological mechanisms are involved in the multifactorial etiology of
15
16 muscle dysfunction in COPD⁴. Interestingly, while both respiratory and peripheral muscles
17
18 are disturbed in the patients, the latter are usually more severely affected and have been
19
20 the matter of abundant research in the last two decades. Besides, current evidence has
21
22 also shown that several cellular and molecular events are differentially expressed in the
23
24 respiratory and limb muscles of patients with COPD. The current editorial aims to provide
25
26 an overview of the most relevant biological mechanisms that have been shown so far to
27
28 participate in the pathophysiology of the lower limb muscle dysfunction in patients with
29
30 COPD.
31
32
33
34
35
36
37
38

39 In the last two decades several advances have been developed in the identification
40
41 of the biological mechanisms that underlie muscle dysfunction in COPD. Elucidation of the
42
43 most relevant contributing mechanisms in this condition will help design therapeutic
44
45 strategies that will alleviate muscle mass loss and dysfunction in patients with COPD. A
46
47 rise in oxidative stress as measured by protein oxidation levels has been repeatedly
48
49 demonstrated in the limb muscles of patients with COPD⁴. Moreover, oxidative stress
50
51 markers were also shown to inversely correlate with clinical parameters such as exercise
52
53 capacity, body composition, and quadriceps strength among patients with COPD⁵. These
54
55 results suggest that oxidative events may hamper muscle function through the induction of
56
57
58
59
60
61
62
63
64
65

1 alterations of key cellular processes involved in muscle contraction. Indeed, the content of
2 several specific muscle proteins such as creatine kinase and myosin heavy chain was
3 reduced in the vastus lateralis of patients with severe COPD and muscle wasting, while a
4 rise in their levels of oxidation was detected in the same **proteins⁵⁻⁷**. Systemic levels of
5 oxidative stress have also been demonstrated in patients with **COPD⁷⁻⁸**.

6
7
8
9
10
11
12 Several markers of the ubiquitin-proteasome system were consistently upregulated
13 in the lower limb muscles of COPD **patients^{4,6,7}**. Moreover, the number of
14 autophagosomes and the expression of other autophagy markers were also increased in
15 the vastus lateralis of patients with severe COPD and muscle mass **loss^{4,7,9}**. Importantly,
16 several redox signaling cellular pathways such as nuclear factor (NF)- κ B and forkhead box
17 (FoxO)1 and FoxO3 are likely to mediate the loss of muscle mass in patients with severe
18 COPD and **cachexia^{6,7}**. Increased levels of terminal deoxynucleotidyl transferase-
19 mediated dUTP nick-end labeling (TUNEL)-positive nuclei were also seen in the vastus
20 lateralis of severe COPD patients with normal body composition, whereas levels of
21 ultrastructural apoptosis were low and did not differ in the muscles of the patients from
22 those detected in the healthy **controls^{4,10}**.

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Epigenetic control of cells, defined as the process whereby gene expression is regulated by heritable mechanisms that do not affect DNA sequence, has recently emerged as a potential biological mechanism that may regulate muscle function and mass in COPD. The epigenetic modifications identified so far in cells are the following: 1) DNA methylation, 2) histone acetylation, 3) histone methylation, and 4) non-coding RNAs such as microRNAs. The epigenetic events modify gene transcription in different ways. For instance, DNA methylation at the 5 position of cytosine specifically reduces gene expression. Acetylation is a transient, enzymatically controlled biochemical process, and the commonest posttranslational modification of histones. Acetylation, a process mediated

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

by histone acetyltransferases (HTA), results in a rather open chromatin structure that is transcriptionally active, while deacetylation through the action of histone deacetylases (HDAC) blocks transcription. Additionally, methylation of histones may activate or repress gene transcription depending on the proteins recruited to the chromatin.

Evaluation of the expression of microRNAs has recently gained much attention in the study of the etiology of respiratory diseases. MicroRNAs, encoded by eukaryotic nuclear DNA, are non-coding single-stranded RNA molecules (18-24 nucleotides) that function in the post-transcriptional regulation of gene expression. Interestingly, they exert their action via base-pairing with complementary sequences in mRNA molecules that result in gene silencing via translational repression or target degradation. MicroRNAs may have different mRNA targets and a given mRNA may also be targeted by multiple microRNAs. MicroRNAs regulate many physiological cellular processes and may play a significant role in the pathogenesis of several lung diseases including lung cancer and COPD.

Recently, several investigations have focused on the analyses of epigenetic modifications in the muscles of COPD patients. As such, in patients with mild COPD, miR-1 expression was increased and positively correlated with the airway obstruction and quadriceps **force**¹¹. Importantly, the expression of miR-1, miR-206, and miR-27a, levels of lysine-acetylated proteins and histones, and acetylated histone 3 were increased in the quadriceps of COPD patients, especially in those with muscle weakness and wasting, while expression of HDAC3, HDAC4, and sirtuin-1 were **reduced**¹². In other experiments, levels of miR-1 levels were lower, while those of HDAC4 were greater in the vastus lateralis of COPD patients with preserved body **composition**¹³. Furthermore, levels of the transcription factor Yin Yang (YY)1, which modifies histones, inversely correlated with the size of slow- and fast-twitch fibers in the limb muscles of COPD patients with normal body

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

composition¹⁴. Interestingly, systemic levels of muscle-specific microRNAs were also upregulated in patients with severe COPD and normal body composition¹⁵. In summary, several epigenetic events that are differentially expressed in the limb muscles of COPD patients with and without muscle mass loss may counterbalance the underlying mechanisms that deteriorate their muscle mass and function.

Future research is still required in order to identify additional mechanisms that may also underlie the etiology of skeletal muscle dysfunction in patients with COPD. We are in the need to identify new cellular and molecular mechanisms that can be specifically targeted using pharmacological strategies and/or exercise training modalities to prevent skeletal muscle from undergoing further functional deterioration and wasting.

Reference List

- 1
2 1. Marquis K, Debigare R, Lacasse Y, LeBlanc P, Jobin J, Carrier G, et al. Midthigh
3 muscle cross-sectional area is a better predictor of mortality than body mass
4 index in patients with chronic obstructive pulmonary disease. *Am J Respir Crit*
5 *Care Med.* 2002;166(6):809-13.
6
- 7
8 2. Seymour JM, Spruit MA, Hopkinson NS, Natanek SA, Man WD, Jackson A, et al.
9 The prevalence of quadriceps weakness in COPD and the relationship with
10 disease severity. *Eur Respir J.* 2010;36(1):81-8.
11
- 12
13 3. Swallow EB, Reyes D, Hopkinson NS, Man WD, Porcher R, Cetti EJ, et al.
14 Quadriceps strength predicts mortality in patients with moderate to severe
15 chronic obstructive pulmonary disease. *Thorax.* 2007;62(2):115-20.
16
- 17
18 4. Barreiro E, Gea J. Molecular and biological pathways of skeletal muscle
19 dysfunction in chronic obstructive pulmonary disease. *Chron Respir Dis.* 2016.
20
- 21
22 5. Barreiro E, Rabinovich R, Marin-Corral J, Barbera JA, Gea J, Roca J. Chronic
23 endurance exercise induces quadriceps nitrosative stress in patients with severe
24 COPD. *Thorax.* 2009;64(1):13-9.
25
- 26
27 6. Fermoselle C, Rabinovich R, Ausin P, Puig-Vilanova E, Coronell C, Sanchez F,
28 et al. Does oxidative stress modulate limb muscle atrophy in severe COPD
29 patients? *Eur Respir J.* 2012;40(4):851-62.
30
- 31
32 7. Puig-Vilanova E, Rodriguez DA, Lloreta J, Ausin P, Pascual-Guardia S,
33 Broquetas J, et al. Oxidative stress, redox signaling pathways, and autophagy in
34 cachectic muscles of male patients with advanced COPD and lung cancer. *Free*
35 *Radic Biol Med.* 2015;79:91-108.
36
- 37
38 8. Rodriguez DA, Kalko S, Puig-Vilanova E, Perez-Olabarria M, Falciani F, Gea J,
39 et al. Muscle and blood redox status after exercise training in severe COPD
40 patients. *Free Radic Biol Med.* 2012;52(1):88-94.
41
- 42
43 9. Guo Y, Gosker HR, Schols AM, Kapchinsky S, Bourbeau J, Sandri M, et al.
44 Autophagy in locomotor muscles of patients with chronic obstructive pulmonary
45 disease. *Am J Respir Crit Care Med.* 2013;188(11):1313-20.
46
- 47
48 10. Barreiro E, Ferrer D, Sanchez F, Minguella J, Marin-Corral J, Martinez-Llorens J,
49 et al. Inflammatory cells and apoptosis in respiratory and limb muscles of patients
50 with COPD. *J Appl Physiol.* 2011;111(3):808-17.
51
- 52
53 11. Puig-Vilanova E, Ausin P, Martinez-Llorens J, Gea J, Barreiro E. Do epigenetic
54 events take place in the vastus lateralis of patients with mild chronic obstructive
55 pulmonary disease? *PLoS One.* 2014;9(7):e102296.
56
- 57
58 12. Puig-Vilanova E, Martinez-Llorens J, Ausin P, Roca J, Gea J, Barreiro E.
59 Quadriceps muscle weakness and atrophy are associated with a differential
60 epigenetic profile in advanced COPD. *Clin Sci (Lond).* 2015;128(12):905-21.
61
62
63
64
65

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
13. Lewis A, Riddoch-Contreras J, Natanek SA, Donaldson A, Man WD, Moxham J, et al. Downregulation of the serum response factor/miR-1 axis in the quadriceps of patients with COPD. *Thorax*. 2012;67(1):26-34.
14. Natanek SA, Riddoch-Contreras J, Marsh GS, Hopkinson NS, Man WD, Moxham J, et al. Yin Yang 1 expression and localisation in quadriceps muscle in COPD. *Arch Bronconeumol*. 2011;47(6):296-302.
15. Donaldson A, Natanek SA, Lewis A, Man WD, Hopkinson NS, Polkey MI, et al. Increased skeletal muscle-specific microRNA in the blood of patients with COPD. *Thorax*. 2013;68(12):1140-9.